vs
Side-by-side financial comparison of Sphere 3D Corp. (ANY) and Bolt Biotherapeutics, Inc. (BOLT). Click either name above to swap in a different company.
Sphere 3D Corp. is the larger business by last-quarter revenue ($2.7M vs $2.5M, roughly 1.1× Bolt Biotherapeutics, Inc.). Over the past eight quarters, Bolt Biotherapeutics, Inc.'s revenue compounded faster (-31.2% CAGR vs -37.4%).
Sphere 3D Corp is a global technology company specializing in cloud computing, data management, and virtualization solutions. It delivers enterprise-grade products and services tailored for small to medium-sized businesses, large enterprise clients, and public sector entities, focusing on optimizing IT infrastructure efficiency and cutting operational costs for end users.
Bolt Biotherapeutics, Inc. is a clinical-stage biotechnology company specializing in immune-stimulating antibody conjugate (ISAC) therapies for cancer treatment. Its core pipeline targets hard-to-treat solid tumors, serving global oncology markets and advancing novel immunotherapies that trigger targeted anti-tumor immune responses to improve patient outcomes.
ANY vs BOLT — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $2.7M | $2.5M |
| Net Profit | — | $-6.6M |
| Gross Margin | — | — |
| Operating Margin | -372.7% | -283.4% |
| Net Margin | — | -265.2% |
| Revenue YoY | 3.1% | — |
| Net Profit YoY | — | 58.4% |
| EPS (diluted) | $-6.96 | $-9.38 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $2.7M | $2.5M | ||
| Q3 25 | $2.6M | $2.2M | ||
| Q2 25 | $3.0M | $1.8M | ||
| Q1 25 | $2.8M | $1.2M | ||
| Q4 24 | $2.6M | $0 | ||
| Q3 24 | $2.4M | $1.1M | ||
| Q2 24 | $4.7M | $1.3M | ||
| Q1 24 | $6.9M | $5.3M |
| Q4 25 | — | $-6.6M | ||
| Q3 25 | $-4.2M | $-7.1M | ||
| Q2 25 | $1.7M | $-8.6M | ||
| Q1 25 | $-8.8M | $-11.0M | ||
| Q4 24 | — | $-15.9M | ||
| Q3 24 | $104.0K | $-15.2M | ||
| Q2 24 | $2.1M | $-21.2M | ||
| Q1 24 | $-4.5M | $-10.8M |
| Q4 25 | — | — | ||
| Q3 25 | 25.4% | — | ||
| Q2 25 | 23.8% | — | ||
| Q1 25 | 22.1% | — | ||
| Q4 24 | — | — | ||
| Q3 24 | -16.0% | — | ||
| Q2 24 | 15.2% | — | ||
| Q1 24 | 38.0% | — |
| Q4 25 | -372.7% | -283.4% | ||
| Q3 25 | -153.8% | -355.1% | ||
| Q2 25 | -87.0% | -510.5% | ||
| Q1 25 | -184.2% | -991.4% | ||
| Q4 24 | -328.7% | — | ||
| Q3 24 | -218.8% | -1441.1% | ||
| Q2 24 | -122.4% | -1772.3% | ||
| Q1 24 | -26.9% | -324.1% |
| Q4 25 | — | -265.2% | ||
| Q3 25 | -162.0% | -329.4% | ||
| Q2 25 | 55.2% | -474.6% | ||
| Q1 25 | -311.9% | -903.4% | ||
| Q4 24 | — | — | ||
| Q3 24 | 4.4% | -1330.1% | ||
| Q2 24 | 45.5% | -1662.4% | ||
| Q1 24 | -64.5% | -205.0% |
| Q4 25 | $-6.96 | $-9.38 | ||
| Q3 25 | $-0.15 | $-3.72 | ||
| Q2 25 | $0.06 | $-4.46 | ||
| Q1 25 | $-0.32 | $-0.29 | ||
| Q4 24 | $-4.62 | $-13.73 | ||
| Q3 24 | $0.01 | $-7.93 | ||
| Q2 24 | $0.10 | $-11.12 | ||
| Q1 24 | $-0.27 | $-0.28 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $3.7M | $27.5M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $23.3M | $26.5M |
| Total Assets | $25.1M | $56.7M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $3.7M | $27.5M | ||
| Q3 25 | $5.3M | $31.9M | ||
| Q2 25 | $4.7M | $34.8M | ||
| Q1 25 | $2.8M | $38.8M | ||
| Q4 24 | $5.4M | $47.3M | ||
| Q3 24 | $5.0M | $53.8M | ||
| Q2 24 | $4.3M | $73.7M | ||
| Q1 24 | $9.3M | $91.3M |
| Q4 25 | $23.3M | $26.5M | ||
| Q3 25 | $29.5M | $32.1M | ||
| Q2 25 | $32.7M | $38.8M | ||
| Q1 25 | $30.7M | $46.8M | ||
| Q4 24 | $39.3M | $57.2M | ||
| Q3 24 | $35.8M | $72.0M | ||
| Q2 24 | $33.4M | $85.9M | ||
| Q1 24 | $27.5M | $104.2M |
| Q4 25 | $25.1M | $56.7M | ||
| Q3 25 | $31.1M | $65.1M | ||
| Q2 25 | $34.4M | $75.5M | ||
| Q1 25 | $34.3M | $85.9M | ||
| Q4 24 | $43.2M | $99.6M | ||
| Q3 24 | $44.3M | $109.3M | ||
| Q2 24 | $44.0M | $124.2M | ||
| Q1 24 | $42.0M | $142.9M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-16.1M | $-7.2M |
| Free Cash FlowOCF − Capex | $-23.6M | — |
| FCF MarginFCF / Revenue | -867.3% | — |
| Capex IntensityCapex / Revenue | 275.4% | — |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $-40.5M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-16.1M | $-7.2M | ||
| Q3 25 | $-3.5M | $-9.7M | ||
| Q2 25 | $-5.8M | $-9.6M | ||
| Q1 25 | $-4.1M | $-13.4M | ||
| Q4 24 | $-4.6M | $-14.4M | ||
| Q3 24 | $290.0K | $-14.0M | ||
| Q2 24 | $-3.3M | $-16.1M | ||
| Q1 24 | $-58.0K | $-16.8M |
| Q4 25 | $-23.6M | — | ||
| Q3 25 | $-5.7M | — | ||
| Q2 25 | $-6.0M | — | ||
| Q1 25 | $-5.1M | — | ||
| Q4 24 | $-13.5M | — | ||
| Q3 24 | $-4.3M | $-14.0M | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | -867.3% | — | ||
| Q3 25 | -218.7% | — | ||
| Q2 25 | -200.5% | — | ||
| Q1 25 | -181.2% | — | ||
| Q4 24 | -511.9% | — | ||
| Q3 24 | -184.4% | -1227.6% | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | 275.4% | — | ||
| Q3 25 | 86.5% | — | ||
| Q2 25 | 6.6% | — | ||
| Q1 25 | 36.4% | — | ||
| Q4 24 | 338.7% | — | ||
| Q3 24 | 196.7% | 3.6% | ||
| Q2 24 | 0.0% | 0.0% | ||
| Q1 24 | 0.0% | 0.0% |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | -3.51× | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 2.79× | — | ||
| Q2 24 | -1.55× | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
